Despite decades of intensive research and numerous drugs brought to clinical trials, there are no drug therapies that can prevent, slow, or cure Alzheimer?s disease. Development of new drugs can take years to complete, so we need to better prioritize the best therapies from the outset. To do this, researchers need a way to share early-stage information about new drug targets and get feedback from the community before the time-intensive process of drug development gets underway. Taking steps toward this goal, Sage Bionetworks announces the launch of the Agora platform, an interactive, web-based tool that allows researchers to share and explore curated genomic analyses of Alzheimer?s Disease (AD). Agora hosts a list of over a hundred nascent drug targets for AD that were nominated by AD researchers as part of the National Institute on Aging?s Accelerating Medicines Partnership- Alzheimer?s Disease (AMP-AD) research program. These early stage targets are being made available in order to integrate additional evidence from external researchers. Early peer feedback will help shape future research directions and should shorten the time it takes to find a cure: http://agora.ampadportal.org Press Release ? http://sagebionetworks.org/research-projects/agora/